Summit Trail Advisors LLC Has $7.37 Million Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Summit Trail Advisors LLC increased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 34.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 365,063 shares of the company’s stock after purchasing an additional 94,279 shares during the period. Summit Trail Advisors LLC owned approximately 0.17% of Hims & Hers Health worth $7,371,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of HIMS. Victory Capital Management Inc. lifted its stake in Hims & Hers Health by 23.0% in the fourth quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock valued at $163,000 after buying an additional 3,429 shares in the last quarter. Diversify Advisory Services LLC acquired a new position in Hims & Hers Health in the 1st quarter worth $701,000. Sei Investments Co. boosted its stake in Hims & Hers Health by 206.9% in the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after purchasing an additional 37,890 shares during the period. Quantbot Technologies LP increased its holdings in Hims & Hers Health by 3,444.9% during the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after purchasing an additional 208,621 shares in the last quarter. Finally, Quadrature Capital Ltd raised its stake in shares of Hims & Hers Health by 494.2% in the 1st quarter. Quadrature Capital Ltd now owns 201,043 shares of the company’s stock valued at $3,108,000 after purchasing an additional 167,211 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on HIMS shares. Jefferies Financial Group upped their price objective on Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. TD Cowen lifted their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Truist Financial increased their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.86.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $16.29 on Friday. The stock has a 50-day simple moving average of $17.35 and a 200 day simple moving average of $17.05. The stock has a market capitalization of $3.50 billion, a P/E ratio of -1,628.50 and a beta of 1.05. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. During the same quarter in the prior year, the business earned ($0.03) EPS. The firm’s revenue for the quarter was up 51.8% on a year-over-year basis. Research analysts forecast that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Insider Activity

In other news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $20.75, for a total transaction of $3,919,426.00. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at $695,166.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $20.75, for a total value of $3,919,426.00. Following the completion of the sale, the chief executive officer now owns 33,502 shares in the company, valued at approximately $695,166.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael Chi sold 2,054 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total transaction of $45,188.00. Following the transaction, the insider now owns 185,326 shares in the company, valued at approximately $4,077,172. The disclosure for this sale can be found here. Insiders have sold 701,904 shares of company stock valued at $12,349,805 over the last ninety days. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.